A novel bispecific adaptor platform enhances CD19-CAR T cell persistence and efficacy in solid tumors

Abstract Chimeric antigen receptor (CAR) T cell therapy has transformed hematological cancer treatment but remains ineffective in solid tumors. Here, we compared CD19-CAR and HER2-CAR T cells with identical backbones in matched tumor models. Strikingly, CD19-CAR T cells eradicated all tested CD19 + solid tumors in vivo , whereas HER2-CAR T cells failed to control matched HER2 + solid tumors. Superior CD19-CAR efficacy was associated with greater avidity, stronger signaling, and rapid degranulation. To harness these favorable properties for solid tumor treatment, we developed and compared bispecific Adaptors redirecting CD19-CAR T cell activity against HER2 + cancers. Our lead nanobody-based Adaptor 4 incorporating an albumin-binding VHH improves upon earlier designs by enhancing manufacturability and tumor infiltration while retaining systemic persistence. It induced complete tumor regression and prolonged survival in two solid tumor models. Mechanistically, Adaptor 4 enhanced CAR T cell-tumor cell engagement, signaling and intratumoral infiltration, accompanied by spatially distinct CAR T cell states and local inflammatory remodeling. Long-term tumor-free mice rejected tumor rechallenge, demonstrating durable antitumor protection. Importantly, Adaptor 4 remained effective when combined with CD19-CAR T cells generated from patients with advanced solid cancers. Together, these findings establish an enhanced Adaptor strategy redirecting clinically validated CD19-CAR T cells for solid tumor treatment.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-17
DOI
https://doi.org/10.21203/rs.3.rs-11591978/v1
Primary Topic
CAR-T cell therapy research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

A novel bispecific adaptor platform enhances CD19-CAR T cell persistence and efficacy in solid tumors

Charbel Darido, Lining Arnold Ju, Yuchen Bai, Joseph A. Trapani et al.
Research Square
CAR-T cell therapy research
preprint

A novel bispecific adaptor platform enhances CD19-CAR T cell persistence and efficacy in solid tumors

Charbel Darido, Lining Arnold Ju, Yuchen Bai, Joseph A. Trapani, Jasmine Jin, Paul Joseph Neeson, Paul D. Rennert, Phillip Kevin Darcy, Rachel Xu, Jie Sun, Bianca von Scheidt, Clare Y. Slaney, Michael John Dickinson, Haoqing Wang, Christine M. Ambrose, Olivia Hidajat, Dmitry Zorin, Brian Liddicoat, Ruihong Huang, Evan Pappas, Xiaomeng Zhang, Yao Wang, Michael Kershaw
preprint en

Abstract

Abstract Chimeric antigen receptor (CAR) T cell therapy has transformed hematological cancer treatment but remains ineffective in solid tumors. Here, we compared CD19-CAR and HER2-CAR T cells with identical backbones in matched tumor models. Strikingly, CD19-CAR T cells eradicated all tested CD19 + solid tumors in vivo , whereas HER2-CAR T cells failed to control matched HER2 + solid tumors. Superior CD19-CAR efficacy was associated with greater avidity, stronger signaling, and rapid degranulation. To harness these favorable properties for solid tumor treatment, we developed and compared bispecific Adaptors redirecting CD19-CAR T cell activity against HER2 + cancers. Our lead nanobody-based Adaptor 4 incorporating an albumin-binding VHH improves upon earlier designs by enhancing manufacturability and tumor infiltration while retaining systemic persistence. It induced complete tumor regression and prolonged survival in two solid tumor models. Mechanistically, Adaptor 4 enhanced CAR T cell-tumor cell engagement, signaling and intratumoral infiltration, accompanied by spatially distinct CAR T cell states and local inflammatory remodeling. Long-term tumor-free mice rejected tumor rechallenge, demonstrating durable antitumor protection. Importantly, Adaptor 4 remained effective when combined with CD19-CAR T cells generated from patients with advanced solid cancers. Together, these findings establish an enhanced Adaptor strategy redirecting clinically validated CD19-CAR T cells for solid tumor treatment.

Research Square
The University of Sydney (AU), The University of Melbourne (AU), Peter MacCallum Cancer Centre (AU), Zhejiang University (CN)
Good health and well-being
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon